J&J
J&J Reports Strong Uptake of Carvykti and Rybrevant in Q4
The company's multiple myeloma franchise, which includes Carvykti, stands to contribute significantly to its growth in 2025.
European Commission Approves Rybrevant, Lazcluze in EGFR-Mutated NSCLC
Patients with advanced lung tumors harboring EGFR exon 19 deletions or exon 21 L858R mutations are eligible for the combo treatment.
Regulators approved the first bespoke cell therapies for solid tumors this year, while drugmakers expanded and improved upon established CAR T-cell therapies.
FDA Issues Complete Response to Johnson & Johnson's Application for Subcutaneous Rybrevant
The agency's decision not to approve this formulation was based on issues identified during a pre-approval inspection at a manufacturing facility, the firm said.
The iMMagine-1 data suggest anito-cel could have a differentiated safety and efficacy profile compared to available BCMA-directed therapies.
Oct 28, 2024
AbbVie to Buy Aliada Therapeutics for $1.4B in Cash
Oct 15, 2024
Oct 24, 2023
Oct 17, 2023